Patents by Inventor Daniel J. Dairaghi

Daniel J. Dairaghi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7262204
    Abstract: Compounds and compositions are provided that bind to the CCR4 chemokine receptor and which are useful for treating diseases associated with CCR4 activity, such as contact hypersensitivity.
    Type: Grant
    Filed: September 2, 2003
    Date of Patent: August 28, 2007
    Assignees: Amgen Inc., ChemoCentryx, Inc.
    Inventors: Tassie Collins, Daniel J. Dairaghi, Hossen Mahmud, Brian E. McMaster, Julio C. Medina, Thomas J. Schall, Feng Xu, Xuemei Wang
  • Patent number: 7132508
    Abstract: A novel CC chemokine which is from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding said chemokine. A chemokine receptor is also provided. Methods of using said reagents and diagnostic kits are also provided.
    Type: Grant
    Filed: November 13, 2002
    Date of Patent: November 7, 2006
    Assignee: Schering Corporation
    Inventors: Daniel J. Dairaghi, Takahiko Hara, Atsushi Miyajima, Thomas J. Schall, Wei Wang, Akihiko Yoshimura
  • Patent number: 7108990
    Abstract: The invention provides polypeptides and polynucleotides encoding a novel chemokine receptor, CCX CKR. The invention further provides reagents and methods for identifying agents that modulate the activity or expression of the receptors, as well as methods for detecting receptor expression.
    Type: Grant
    Filed: February 24, 2004
    Date of Patent: September 19, 2006
    Assignee: ChemoCentryx, Inc.
    Inventors: Jennifa Gosling, Daniel J. Dairaghi, Michael Hanley, Zhenhua Miao, Thomas J. Schall
  • Patent number: 7101894
    Abstract: Methods for treating CMV or a CMV-related disease are provided that use compounds having the formula: wherein Ar is a substituted or unsubstituted 5–14 membered heteroaryl group having from 1 to 5 heteroatoms as ring members; R1 is selected from the group consisting of substituted or unsubstituted aryl(C1–C4)alkyl, heteroaryl(C1–C4)alkyl, —C(O)R11, and —C(O)NR11R12, wherein each R11 and R12 independently is substituted or unsubstituted aryl, substituted or unsubstituted aryl(C1–C4)alkyl, substituted or unsubstituted (C4–C8)cycloalkyl(C1–C4)alkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heteroaryl(C1–C4)alkyl and substituted or unsubstituted hetero(C4–C8)cycloalkyl(C1–C4)alkyl; R2 is H or (C1–C8)alkyl; and ZN is a substituted or unsubstituted hetero(C6–C10)bicycloalkyl group.
    Type: Grant
    Filed: August 29, 2002
    Date of Patent: September 5, 2006
    Assignee: ChemoCentryx, Inc.
    Inventors: Brian E. McMaster, Thomas J. Schall, Mark Penfold, J. J. Wright, Daniel J. Dairaghi
  • Patent number: 6998239
    Abstract: The invention provides polypeptides and polynucleotides encoding a novel chemokine receptor, CCX CKR. The invention further provides reagents and methods for identifying agents that modulate the activity or expression of the receptors, as well as methods for detecting receptor expression.
    Type: Grant
    Filed: November 21, 2000
    Date of Patent: February 14, 2006
    Assignee: ChemoCentryx, Inc.
    Inventors: Jennifa Gosling, Daniel J. Dairaghi, Michael Hanley, Zhenhua Miao, Dale Talbot, Thomas J. Schall
  • Patent number: 6992084
    Abstract: The invention provides compounds and compositions of the formula: wherein, the subscript n is an integer of from 0 to 4; Ar is a member selected from the group consisting of substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl, R1 is a member selected from the group consisting of substituted or unsubstituted (C5–C15)alkyl and (C8–C14)acyl group; R2 is a member selected from the group consisting of substituted or unsubstituted (C1–C8)alkyl; each R3 is independently a substituent Y is a member selected from the group consisting of substituted or unsubstituted (C2–C8)alkylene and substituted or unsubstituted (C2–C8)heteroalkylene; Z is —NR4R5 R4 and R5 are independently selected from the group consisting of hydrogen and (C1–C8)alkyl or taken together with the nitrogen atom to which each is attached to form a heterocyclyl or heteroaryl; These compounds and compositions bind to the CXCR3 chemokine receptor and are useful for treating diseases and conditions responsive to the mo
    Type: Grant
    Filed: October 23, 2002
    Date of Patent: January 31, 2006
    Assignee: ChemoCentryx, Inc.
    Inventors: Thomas J. Schall, Daniel J. Dairaghi, Brian E. McMaster
  • Patent number: 6835547
    Abstract: The invention provides polypeptides and polynucleotides encoding a novel chemokine receptor, CCX CKR. The invention further provides reagents and methods for identifying agents that modulate the activity or expression of the receptors, as well as methods for detecting receptor expression.
    Type: Grant
    Filed: November 21, 2000
    Date of Patent: December 28, 2004
    Assignee: ChemoCentryx, Inc.
    Inventors: Jennifa Gosling, Daniel J. Dairaghi, Michael Hanley, Zhenhua Miao, Dale Talbot, Thomas J. Schall
  • Patent number: 6821998
    Abstract: Methods for treating CMV and CMV-related diseases are provided that use compounds having the formula: wherein the subscripts m and n are each independently integers from 1 to 2; and the R groups are as defined in the specification.
    Type: Grant
    Filed: August 29, 2002
    Date of Patent: November 23, 2004
    Assignee: ChemoCentryx, Inc.
    Inventors: Brian E. McMaster, Thomas J. Schall, Mark Penfold, J. J. Wright, Daniel J. Dairaghi
  • Publication number: 20040146926
    Abstract: The invention provides polypeptides and polynucleotides encoding a novel chemokine receptor, CCX CKR. The invention further provides reagents and methods for identifying agents that modulate the activity or expression of the receptors, as well as methods for detecting receptor expression.
    Type: Application
    Filed: February 24, 2004
    Publication date: July 29, 2004
    Applicant: ChemoCentryx, Inc.
    Inventors: Jennifa Gosling, Daniel J. Dairaghi, Michael Hanley, Zhenhua Miao, Dale Talbot, Thomas J. Schall
  • Publication number: 20040039035
    Abstract: Compounds and compositions are provided that bind to the CCR4 chemokine receptor and which are useful for treating diseases associated with CCR4 activity, such as contact hypersensitivity.
    Type: Application
    Filed: September 2, 2003
    Publication date: February 26, 2004
    Applicants: Tularik Inc., ChemoCentryx, Inc.
    Inventors: Tassie Collins, Daniel J. Dairaghi, Hossen Mahmud, Brian E. McMaster, Julio C. Medina, Thomas J. Schall, Feng Xu, Xuemei Wang
  • Publication number: 20030149055
    Abstract: Methods for treating CMV or a CMV-related disease are provided that use compounds having the formula: 1
    Type: Application
    Filed: August 29, 2002
    Publication date: August 7, 2003
    Applicant: ChemoCentryx
    Inventors: Brian E. McMaster, Thomas J. Schall, Mark Penfold, J. J. Wright, Daniel J. Dairaghi
  • Publication number: 20030130494
    Abstract: A novel CC chemokine which is from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding said chemokine. A chemokine receptor is also provided. Methods of using said reagents and diagnostic kits are also provided.
    Type: Application
    Filed: November 13, 2002
    Publication date: July 10, 2003
    Inventors: Daniel J. Dairaghi, Takahiko Hara, Atsushi Miyajima, Thomas J. Schall, Wei Wang, Akihiko Yoshimura
  • Publication number: 20030119854
    Abstract: Compounds and compositions are provided that bind to the CXCR3 chemokine receptor and which are useful for treating diseases associated with CXCR3 activity, such as multiple sclerosis.
    Type: Application
    Filed: October 23, 2002
    Publication date: June 26, 2003
    Applicant: ChemoCentryx, Inc.
    Inventors: Thomas J. Schall, Daniel J. Dairaghi, Brian E. McMaster
  • Publication number: 20030114423
    Abstract: Methods for treating CMV and CMV-related diseases are provided that use compounds having the formula: 1
    Type: Application
    Filed: August 29, 2002
    Publication date: June 19, 2003
    Applicant: ChemoCentryx, Inc.
    Inventors: Brian E. McMaster, Thomas J. Schall, Mark Penfold, J.J. Wright, Daniel J. Dairaghi
  • Patent number: 6559160
    Abstract: The invention provides compounds and compositions of the formula: wherein the subscript n is an integer of from 0 to 4; Ar is a member selected from the group consisting of substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl; R1 is a member selected from the group consisting of substituted or unsubstituted (C5-C15)alkyl; R2 is a member selected from the group consisting of substituted or unsubstituted (C1-C8)alkyl; each R3 is independently a substituent selected from -halogen, —OR′, —OC(O)R′, —NR′R″, —SR′, —R′, —CN, —NO2, —CO2R′, —CONR′R″, —C(O)R′, —OC(O)NR′R″, —NR″C(O)R′, —NR″C(O)2R′, , —NR′—C(O)NR″R′″, —NH—C(NH2)═NH, —NR′C(NH2)═NH, —NH—C(NH2)═NR—, —S(O)R′, —S(O)2R′, —
    Type: Grant
    Filed: August 25, 2000
    Date of Patent: May 6, 2003
    Assignee: Chemocentryx, Inc.
    Inventors: Thomas J. Schall, Daniel J. Dairaghi, Brian E. McMaster
  • Patent number: 6512103
    Abstract: A novel CC chemokine which is from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding said chemokine. A chemokine receptor is also provided. Methods of using said reagents and diagnostic kits are also provided.
    Type: Grant
    Filed: December 8, 1995
    Date of Patent: January 28, 2003
    Assignee: Schering Corporation
    Inventors: Daniel J. Dairaghi, Takahiko Hara, Atsushi Miyajima, Thomas J. Schall, Wei Wang, Akihiko Yoshimura
  • Publication number: 20020193374
    Abstract: Methods are provided for detecting the spread of cytomegalovirus in a host infected with CMV, by administering to the host a detectable and labeled amount of a non-endogenous compound which binds to US28 or a US28 fragment. Typically, the methods use a labeled form of IBZM.
    Type: Application
    Filed: August 30, 2001
    Publication date: December 19, 2002
    Applicant: ChemoCentryx
    Inventors: Thomas J. Schall, Brian E. McMaster, Daniel J. Dairaghi
  • Publication number: 20020173524
    Abstract: Compounds and compositions are provided that bind to the CCR4 chemokine receptor and which are useful for treating diseases associated with CCR4 activity, such as contact hypersensitivity.
    Type: Application
    Filed: October 11, 2001
    Publication date: November 21, 2002
    Applicant: Tularik Inc.
    Inventors: Tassie Collins, Daniel J. Dairaghi, Hossen Mahmud, Brian E. McMaster, Julio C. Medina, Thomas J. Schall, Feng Xu, Xuemei Wang
  • Publication number: 20020132836
    Abstract: Compounds and compositions are provided that bind to the CCR4 chemokine receptor and which are useful for treating diseases associated with CCR4 activity, such as contact hypersensitivity.
    Type: Application
    Filed: October 11, 2001
    Publication date: September 19, 2002
    Applicant: ChemoCentryx Inc.
    Inventors: Daniel J. Dairaghi, Brian E. McMaster, Thomas J. Schall
  • Patent number: RE39849
    Abstract: The invention provides polypeptides and polynucleotides encoding a novel chemokine receptor, CCX CKR. The invention further provides reagents and methods for identifying agents that modulate the activity or expression of the receptors, as well as methods for detecting receptor expression.
    Type: Grant
    Filed: December 29, 2005
    Date of Patent: September 18, 2007
    Assignee: ChemoCentryx, Inc.
    Inventors: Jennifa Gosling, Daniel J. Dairaghi, Michael Hanley, Zhenhua Miao, Thomas J. Schall